Work

A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.2611

Authors: Roger B. Cohen, Melissa Lynne Johnson, Przemyslaw Twardowski, Mark N. Stein, Ulka N. Vaishampayan, Jason R. Dobson, James Foti, Parul Agnihotri, Louisa Dowal, Wendy Broom, Lisa McNeil, Thomas A. Davis, Jessica Flechtner

Institutions: University of Pennsylvania, Sarah Cannon, Saint John's Health Center, Columbia University Irving Medical Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Genocea (United States)

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947123000

Cites:

Cited by: 5

Related to: 10